kabutan

FunPep Company Limited(4881) Summary

4881
TSE Growth
FunPep Company Limited
70
JPY
0
(0.00%)
Apr 30, 9:01 am JST
0.43
USD
Apr 29, 8:01 pm EDT
Result
PTS
outside of trading hours
70.1
Apr 30, 9:01 am JST
Summary Chart Historical News Financial Result
PER
PBR
2.18
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 30, 2026
Opening Apr 30, 9:00 am
70 JPY 0.43 USD
Previous Close Apr 28
70 JPY 0.43 USD
High Apr 30, 9:00 am
70 JPY 0.43 USD
Low Apr 30, 9:00 am
70 JPY 0.43 USD
Volume
185,500
Trading Value
0.01B JPY 0.08M USD
VWAP
70.0 JPY 0.44 USD
Minimum Trading Value
7,000 JPY 43 USD
Market Cap
3.14B JPY 0.02B USD
Number of Trades
18
Liquidity & Number of Trades
As of Apr 30, 2026
Liquidity
Mid
1-Year Average
280
1-Year High Mar 6, 2026
5,097
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 5,748,600
Apr 17, 2026 0 5,815,800
Apr 10, 2026 0 5,777,500
Apr 3, 2026 0 5,697,800
Mar 27, 2026 0 5,707,300
Company Profile
FunPep Company Limited is a spin-off from Osaka University's Institute for Protein Research, focusing on research and development of pharmaceuticals using functional peptides.
Sector
Pharmaceuticals
FunPep Company Limited engages in the research and development of pharmaceuticals and other products using functional peptides. The company's strength lies in its proprietary drug discovery platform technology "STEP UP" for antibody-inducing peptides, enabling the creation of development candidates for various target proteins as alternatives to antibody drugs. Additionally, FunPep is advancing the development of SR-0379, a treatment for skin ulcers. The company aims to generate new development candidates through collaborative research with universities and promotes development through partnerships with pharmaceutical companies. In the future, FunPep aspires to achieve significant profit growth through royalty income from the commercialization of its development products. The company's mission is to contribute to society by developing new pharmaceuticals that help reduce medical costs and patient burden.